9/14/2026
Psyence BioMed launches US ibogaine subsidiary
New Texas-based entity to spearhead ibogaine research and development in the US.
Topic archive
united states
38 stories
9/14/2026
Psyence BioMed expands U.S. ibogaine research with Texas unit
New subsidiary aims to centralize ibogaine supply and regulatory efforts in the U.S.
9/14/2026
Psyence BioMed forms Texas entity for U.S. ibogaine research
Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.
9/11/2026
Ibogaine's potential in opioid addiction treatment
Ibogaine offers a novel approach to opioid detox, but carries significant risks.
9/10/2026
Rhelion Life Sciences launches stability program for ibogaine
Filament Health begins stability testing for IBEX011, a botanical ibogaine drug.
9/10/2026
Rhelion Life Sciences launches ibogaine stability program
Filament Health begins stability program for IBEX011 amid rising ibogaine demand.
9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
9/10/2026
Filament Health plans stability program for ibogaine drug
IBEX011 stability program aims to meet growing demand for standardized ibogaine.
9/4/2026
Federal report urges states to prepare for psychedelics
States advised to anticipate FDA approval of psychedelics for medical use.
9/1/2026
Barrow, ASU launch clinical trial for ibogaine in the US
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/26/2026
Americans face risks at overseas psychedelic clinics
Ibogaine treatments in Mexico raise safety concerns for U.S. patients.
8/26/2026
Veterans advocate for ibogaine to combat PTSD
Ibogaine shows promise for PTSD, but remains illegal in the U.S.
8/20/2026
Doctor critical of abortion meds nominated for FDA leadership
Nominee previously advocated for tighter controls on abortion medications.
8/19/2026
Trump's FDA pick Overton may boost psychedelics, pain meds
Heidi Overton's nomination could advance psychedelic therapies but raises vaccine concerns.
8/19/2026
Trump pushes ibogaine treatment for veterans
Trump's administration advances psychedelic therapies for PTSD and TBI in veterans.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Psyence Biomedical welcomes U.S. support for ibogaine
U.S. backing could accelerate ibogaine research for mental health.
8/19/2026
Trump supports psychedelic drugs for veterans' mental health
Former President Trump advocates for psychedelic treatment to aid veterans.
8/19/2026
Psyence BioMed backs Trump ibogaine initiative
Company aligns with U.S. efforts to advance ibogaine research.
8/19/2026
Trump highlights ibogaine research in executive order
Ibogaine, a psychedelic drug, gains federal attention for treating addiction.
8/18/2026
Puerto Rico advances psychedelic therapy research
Governor's order initiates ibogaine, MDMA, and psilocybin study
8/18/2026
Ibogaine's legal status in the US explained
Ibogaine remains illegal in the US despite its potential therapeutic benefits.
8/15/2026
Ibogaine offers new hope for kratom users amid bans
David Dardashti advocates ibogaine as a medical solution for kratom dependency.
8/12/2026
UC Irvine explores ibogaine for opioid addiction
Researchers at UC Irvine investigate ibogaine's potential in opioid use disorder treatment.
8/10/2026
Ibogaine trials for opioid use disorder get ARPA-H boost
ARPA-H seeks to accelerate ibogaine trials for opioid treatment
8/7/2026
Arizona funds $5M ibogaine trial for brain injury
Study explores ibogaine's potential for TBI, amid safety concerns and federal illegality.
8/4/2026
Ibogaine clinic adopts Jungian approach for trauma
Minimalist therapy model emphasizes patient-led recovery
7/31/2026
Ibogaine research gains momentum in Mississippi
Mississippi explores ibogaine trials for addiction treatment, reflecting a shift towards health-centered drug policies.
7/29/2026
Scottsdale Research Institute submits IND for ibogaine
Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.
7/24/2026
White House debates psychedelic health policy
Internal discussions focus on potential therapeutic uses and regulatory challenges.
7/24/2026
Heidi Overton's role in Trump's ibogaine policy
White House adviser Heidi Overton shapes ibogaine policy amid internal disputes.
7/24/2026
Trump administration fast-tracks ibogaine research
Psychoactive drug ibogaine gains attention for addiction treatment potential.
7/24/2026
Ibogaine may gain U.S. access under Trump administration
The Trump administration considers making ibogaine available for therapeutic use.
7/23/2026
Ibogaine access expanded for veterans in FY27 NDAA
New provisions in the NDAA aim to enhance veteran care and strengthen global defense partnerships.
7/22/2026
McCaul advocates for ibogaine access for veterans
Proposed NDAA amendment aims to expand treatment options for PTSD and TBI.
7/22/2026
Federal agencies advance psychedelic therapy post-Trump order
Trump's 2026 executive order boosts psychedelic research funding and collaboration.
7/15/2026
HHS and VA collaborate to advance psychedelic therapy
New agreement includes ibogaine research for opioid use disorder.
7/8/2026
Ibogaine's Legal Status and Clinical Trials
An Overview of Ibogaine's Journey in the U.S.